Binding Agents That Modulate the Hippo Pathway and Uses Thereof

• US 20140056890A1
• Filed: 06/06/2013
• Published: 02/27/2014
• Est. Priority Date: 06/06/2012
• Status: Abandoned Application

• Current Assignee: OncoMed Pharmaceuticals, Incorporated (Mereo BioPharma Group Plc)
• Original Assignee: OncoMed Pharmaceuticals, Incorporated (Mereo BioPharma Group Plc)
• Inventors: GURNEY, Austin L., Chartier-Courtaud, Cecile
• Application Number:
  US13/911,756
• Publication Number:
  US 20140056890A1
• Time in Patent Office: Days
• US Class Current: 424/134.1
• CPC Class Codes: A61K 38/1774 Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to agents that modulate the Hippo pathway and Hippo pathway signaling, such as antibodies and soluble receptors, as well as to methods of using the agents for the treatment of diseases such as cancer.

Claims

1-80. -80. (canceled)

81. An agent that specifically binds the extracellular domain of one or more cell adhesion molecules of the immunoglobulin superfamily (IgCAM), wherein the IgCAM is selected from the group consisting of:

AMICA, CAR, CLMP, ESAM, GPA33, VSIG1, VSIG2, VSIG3, VSIG4, VSIG8, JAM1, JAM2, JAM3, CADM1, CADM2, CADM3, CADM4, CRTAM, TMIGD1, PVR, PVRL1, PVRL2, PVRL3, PVRL4, PVRIG, CD200, CD200R1, CD200R1L, CD226, CD96, TIGIT, and TMEM25.

82. The agent of claim 81, which is a soluble receptor.

83. The agent of claim 82, wherein the soluble receptor comprises:

(a) the extracellular domain of an IgCAM or a portion thereof;

(b) a sequence selected from the group consisting of;

SEQ ID NOs;

33-64;

or

(c) a portion of a sequence selected from the group consisting of;

SEQ ID NOs;

33-64.

84. The agent of claim 82, wherein the soluble receptor comprises the extracellular domain of CADM1, CADM3, PVRL1, PVRL2, or PVRL3, or a portion thereof.

85. The agent of claim 82, which further comprises a Fc region.

86. The agent of claim 81, which is an antibody.

87. The agent of claim 86, wherein the antibody is a monoclonal antibody, a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, an antibody fragment comprising an antigen-binding site, or a bispecific antibody.

88. The agent of claim 81, which:

(a) modulates the Hippo pathway;

(b) activates or increases Hippo pathway signaling;

(c) reduces YAP activity;

(d) increases phosphorylated YAP;

(e) decreases the expression of YAP-dependent genes; and

/or

(f) decreases the expression of at least one of the genes selected from the group consisting of;

CD44, CD47, CD133, TDGF1, EPHB2, CA12, LRP4, GPC4, CLDN2, CTGF, PAG1, SEMA4D, RHEB, MAGI1, ITPR3, CD168, NRP2, Gli2, Birc2, Birc5, FGF1, IL33, GRB2, IGFBP3, and AREG.

89. The agent of claim 81, which:

(a) modulates apoptosis;

(b) modulates cellular proliferation; and

/or

(c) modulates epithelial mesenchymal transition (EMT).

90. The agent of claim 81, which inhibits the growth of a tumor or tumor cells.

91. The agent of claim 90, wherein the tumor is a tumor selected from the group consisting of colorectal tumor, colon tumor, pancreatic tumor, lung tumor, ovarian tumor, liver tumor, breast tumor, kidney tumor, prostate tumor, melanoma, cervical tumor, bladder tumor, brain tumor, gastrointestinal tumor, and head and neck tumor.

92. A pharmaceutical composition comprising the agent of claim 81 and a pharmaceutically acceptable carrier.

93. A cell producing the agent of claim 81.

94. A polynucleotide comprising a polynucleotide that encodes the agent of claim 81.

95. A method of inhibiting tumor growth comprising contacting a tumor or tumor cell with the agent of claim 81.

96. The method of claim 95, wherein the tumor is a tumor selected from the group consisting of colorectal tumor, colon tumor, pancreatic tumor, lung tumor, ovarian tumor, liver tumor, breast tumor, kidney tumor, prostate tumor, melanoma, cervical tumor, bladder tumor, brain tumor, gastrointestinal tumor, and head and neck tumor.

97. A method of treating cancer in a subject, comprising administering a therapeutically effective amount of the agent of claim 81 to the subject.

98. The method of claim 97, wherein the cancer is selected from the group consisting of:

colorectal cancer, colon cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, kidney cancer, prostate cancer, melanoma, cervical cancer, bladder cancer, brain cancer, gastrointestinal cancer, and head and neck cancer.

99. The method of claim 97, which further comprises administering a therapeutically effective amount of a second therapeutic agent to the subject.

100. The method of claim 99, wherein the second therapeutic agent is a chemotherapeutic agent or an antibody.

101. A method of modulating the Hippo pathway in a cell, comprising contacting the cell with the agent of claim 81.